Envudeucitinib

DB21716InvestigationalSmall molecule

Envudeucitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Envudeucitinib is a Janus kinase inhibitor. Envudeucitinib has a monoisotopic molecular weight...

Mechanism: Pharmacologically active on Non-receptor tyrosine-protein kinase TYK2
Curator reviewed
Formula / weight: C₂₂H₂₄N₆O₃ · 426.51 g/mol (avg)
Code names: ESK-001

Resolves to

Compound

UNIIKD2MDJ4GABCAS2417135-66-9ChEMBLCHEMBL5415395ChEBI759831PubChem158715582

Structure

InChIKeyFKCATCQHVCOBCX-WFGJKAKNSA-NSMILES[2H]C([2H])([2H])CC(=O)C1=C(NC2=CC=CC(C3=NN(C=N3)C([2H])([2H])[2H])=C2OC)C=C(NC(=O)C2CC2)N=C1

Targets

P29597TYK2

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Envudeucitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account